Skip to main content
Top
Published in: Clinical and Molecular Allergy 1/2017

Open Access 01-12-2017 | Review

Tolerated drugs in subjects with severe cutaneous adverse reactions (SCARs) induced by anticonvulsants and review of the literature

Authors: Fabrizio De Luca, Laura Michelina Losappio, Corrado Mirone, Jan Walter Schroeder, Antonella Citterio, Maria Gloria Aversano, Joseph Scibilia, Elide Anna Pastorello

Published in: Clinical and Molecular Allergy | Issue 1/2017

Login to get access

Abstract

Background

Anticonvulsant hypersensitivity syndrome represents a rare but potentially fatal kind of adverse drug reaction. This clinical picture often hampers the flexibility with which alternative anticonvulsants or even other classes of drugs are prescribed in these patients, negatively affecting the efficacy of treatment and the course of the disease. The aim of this study was to analyse a group of six patients with severe cutaneous drug reactions induced by anticonvulsants and to report which alternative antiepileptic drugs and which drugs of other classes were tolerated.

Case presentation

A total of six patients (2 males and 4 females, age 11–73 years) are described in this study. In all the patients the onset of the severe cutaneous drug reactions was 2–4 weeks after initiating the anticonvulsant therapy: 2 out of 6 patients presented with a drug reaction with eosinophilia and systemic symptoms under therapy with phenytoin; 2 out of 6 presented with Stevens–Johnson syndrome under therapy with lamotrigine; and 2 out of 6 presented with a toxic epidermal necrolysis, one of them under therapy with valproic acid, and the other one under therapy with lamotrigine. Alternative anticonvulsants tolerated after the reaction were: clonazepam, levetiracetam, diazepam, delorazepam and lormetazepam.

Conclusions

In our cases we observed that non aromatic anticonvulsants and benzodiazepines were well tolerated as alternative treatments in six patients with reactions to aromatic anticonvulsivants and that the risk of hypersensitivity reactions to other drug classes was not increased as compared to general population.
Literature
1.
go back to reference Knowles SR, Shapiro LE, Shear N. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf. 1999;21(6):489–501.CrossRefPubMed Knowles SR, Shapiro LE, Shear N. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf. 1999;21(6):489–501.CrossRefPubMed
2.
go back to reference Wang X, Wang HF, Hang X, Au S, Huang X, Zhang JT, Tian CL, Lang SY. Lamotrigine induced DIHS/DRESS: manifestations, treatment, and outcome in 57 patients. Clin Neurol Neurosurg. 2015;138:1–7.CrossRefPubMed Wang X, Wang HF, Hang X, Au S, Huang X, Zhang JT, Tian CL, Lang SY. Lamotrigine induced DIHS/DRESS: manifestations, treatment, and outcome in 57 patients. Clin Neurol Neurosurg. 2015;138:1–7.CrossRefPubMed
3.
go back to reference Nanau RM, Neuman MG. Adverse drug reactions induced by valproic acid. Clin Biochem. 2013;46(15):1323–38.CrossRefPubMed Nanau RM, Neuman MG. Adverse drug reactions induced by valproic acid. Clin Biochem. 2013;46(15):1323–38.CrossRefPubMed
4.
go back to reference Blaszczyk B, Lason W, Czuczwar SJ. Antiepilectic drugs and adverse skin reactions: an update. Pharmacol Rep. 2015;67(3):426–34.CrossRefPubMed Blaszczyk B, Lason W, Czuczwar SJ. Antiepilectic drugs and adverse skin reactions: an update. Pharmacol Rep. 2015;67(3):426–34.CrossRefPubMed
5.
go back to reference Armin S, Chavoshzadeh Z, Mohkam M, Rezaei N. Antiepileptic hypersensitivity and DRESS syndrome due to phenytoin in two pediatric cases. Turk J Pediatr. 2009;51(1):76–7.PubMed Armin S, Chavoshzadeh Z, Mohkam M, Rezaei N. Antiepileptic hypersensitivity and DRESS syndrome due to phenytoin in two pediatric cases. Turk J Pediatr. 2009;51(1):76–7.PubMed
6.
go back to reference Eginli A, Shah K, Watkins C, Krishnaswamy G. Stevens–Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol. 2017;118(2):143–7.CrossRefPubMed Eginli A, Shah K, Watkins C, Krishnaswamy G. Stevens–Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol. 2017;118(2):143–7.CrossRefPubMed
7.
go back to reference Bocquet H, Bagon M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (DrugRash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg. 1996;15(4):250–7.CrossRefPubMed Bocquet H, Bagon M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (DrugRash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg. 1996;15(4):250–7.CrossRefPubMed
8.
go back to reference Chan HL, Stern RS, Arndt KA, Langlois J, Jick H, Walker AM. The incidence of erythema multiforme, Stevens–Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990;126(1):43–7.CrossRefPubMed Chan HL, Stern RS, Arndt KA, Langlois J, Jick H, Walker AM. The incidence of erythema multiforme, Stevens–Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990;126(1):43–7.CrossRefPubMed
9.
go back to reference Knowles SR, Shear NH. Anticonvulsant hypersensitivity syndrome: an update. Expert Opin Drug Saf. 2012;11(5):767–78.CrossRefPubMed Knowles SR, Shear NH. Anticonvulsant hypersensitivity syndrome: an update. Expert Opin Drug Saf. 2012;11(5):767–78.CrossRefPubMed
10.
go back to reference Paul C, Wolkenstein P, Adle H, Wechsler J, Garchon HJ, Revuz J, Roujeau JC. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol. 1996;134:710.CrossRefPubMed Paul C, Wolkenstein P, Adle H, Wechsler J, Garchon HJ, Revuz J, Roujeau JC. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol. 1996;134:710.CrossRefPubMed
11.
go back to reference Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: a marker for Stevens–Johnson syndrome. Nature. 2004;28(6982):486.CrossRef Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: a marker for Stevens–Johnson syndrome. Nature. 2004;28(6982):486.CrossRef
12.
go back to reference Tassaneeyakul W, Tiamkao S, Jantararoungtong T, Chen P, Lin SY, Chen WH. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia. 2010;51:926.CrossRefPubMed Tassaneeyakul W, Tiamkao S, Jantararoungtong T, Chen P, Lin SY, Chen WH. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia. 2010;51:926.CrossRefPubMed
13.
go back to reference Nguyen DV, Chu HC, Nguyen DV, Phan MH, Craig T, Baumgart K, van Nunen S. HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese. Asia Pac Allergy. 2015;5(2):68–77.CrossRefPubMedPubMedCentral Nguyen DV, Chu HC, Nguyen DV, Phan MH, Craig T, Baumgart K, van Nunen S. HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese. Asia Pac Allergy. 2015;5(2):68–77.CrossRefPubMedPubMedCentral
14.
go back to reference McCormack M, Alfirevic A, Bourgeois S, Farrell JJ. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364(12):1134–43.CrossRefPubMedPubMedCentral McCormack M, Alfirevic A, Bourgeois S, Farrell JJ. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364(12):1134–43.CrossRefPubMedPubMedCentral
15.
go back to reference Genin E, Chen DP, Hung SI, Sekula P, Schumacher M, Chang PY, Tsai SH, Wu TL, Bellòn T, Tamouza R, Fortier C, Tounbert A, Charon D, Hovnanian A, Wolkenstein P, Chung WH, Mockenhaupt M, Roujeau JC. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysìs. Pharmacogen J. 2014;14:281–8.CrossRef Genin E, Chen DP, Hung SI, Sekula P, Schumacher M, Chang PY, Tsai SH, Wu TL, Bellòn T, Tamouza R, Fortier C, Tounbert A, Charon D, Hovnanian A, Wolkenstein P, Chung WH, Mockenhaupt M, Roujeau JC. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysìs. Pharmacogen J. 2014;14:281–8.CrossRef
16.
go back to reference Chang CC, Ng CC, Too CL, Choon SE, Lee CK, Chung WH, Hussei SH, Lim KS, Murad S. Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population. Pharmacogen J. 2017;17:170–3.CrossRef Chang CC, Ng CC, Too CL, Choon SE, Lee CK, Chung WH, Hussei SH, Lim KS, Murad S. Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population. Pharmacogen J. 2017;17:170–3.CrossRef
17.
go back to reference Pichler WJ, Hausmann O. Classification of drug hypersensitivity into allergic, p-1, and pseudo-allergic forms. Int Arch Allergy Immunol. 2016;171:166–79.CrossRefPubMed Pichler WJ, Hausmann O. Classification of drug hypersensitivity into allergic, p-1, and pseudo-allergic forms. Int Arch Allergy Immunol. 2016;171:166–79.CrossRefPubMed
18.
go back to reference Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, Khan DA, Lang DM, Park HS, Pichler W, Sanchez-Borges M, Shiohara T, Thong BY. International consensus on drug allergy. Allergy. 2014;69:420–37.CrossRefPubMed Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, Khan DA, Lang DM, Park HS, Pichler W, Sanchez-Borges M, Shiohara T, Thong BY. International consensus on drug allergy. Allergy. 2014;69:420–37.CrossRefPubMed
19.
go back to reference Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu Y, Creamer D, Sidoroff A, Naldi L, Mockenhaupt M, Roujeay JC. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169:1071–80.CrossRefPubMed Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu Y, Creamer D, Sidoroff A, Naldi L, Mockenhaupt M, Roujeay JC. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169:1071–80.CrossRefPubMed
20.
go back to reference Papay J, Yueu N, Powell G, Mockenhaupt M, Bogenrieder T. Spontaneous adverse event reports of Stevens–Johnson syndrome/toxic epidermal necrolysis: detecting associations with medications. Pharmacoepidemiol Drug Saf. 2012;21:289–96.CrossRefPubMed Papay J, Yueu N, Powell G, Mockenhaupt M, Bogenrieder T. Spontaneous adverse event reports of Stevens–Johnson syndrome/toxic epidermal necrolysis: detecting associations with medications. Pharmacoepidemiol Drug Saf. 2012;21:289–96.CrossRefPubMed
21.
go back to reference Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, Roujeau JC. The DRESS syndrome: a literature review. Am J Med. 2011;124(7):588–97.CrossRefPubMed Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, Roujeau JC. The DRESS syndrome: a literature review. Am J Med. 2011;124(7):588–97.CrossRefPubMed
22.
go back to reference Sassolas B, Haddan C, Mockenhaupt M, Dunat A, Liss Y, Bork K, Haustein UF, Vieluf D, Roujeau JC, Le Louet H. ALDEN, an algorithm for assessment of drug causality in Stevens–Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010;88:60–8.CrossRefPubMed Sassolas B, Haddan C, Mockenhaupt M, Dunat A, Liss Y, Bork K, Haustein UF, Vieluf D, Roujeau JC, Le Louet H. ALDEN, an algorithm for assessment of drug causality in Stevens–Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010;88:60–8.CrossRefPubMed
23.
go back to reference Mockenhaupt M, Viboud C, Dunand A, Naldi L, Halevy S, Bouwer Bavinck HN, Sidoroff A, Schneck J, Roujean JC, Flahault A. Stevens–Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128:35–44.CrossRefPubMed Mockenhaupt M, Viboud C, Dunand A, Naldi L, Halevy S, Bouwer Bavinck HN, Sidoroff A, Schneck J, Roujean JC, Flahault A. Stevens–Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128:35–44.CrossRefPubMed
24.
go back to reference Arif H, Burchsbaum R, Weintraub D, Koyfman S, Salas-Humara C, Bazil CW, Resor SR Jr, Hirsvh LJ. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology. 2007;68(20):1701–9.CrossRefPubMed Arif H, Burchsbaum R, Weintraub D, Koyfman S, Salas-Humara C, Bazil CW, Resor SR Jr, Hirsvh LJ. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology. 2007;68(20):1701–9.CrossRefPubMed
25.
26.
go back to reference Ye YM, Thong BY, Park HS. Hypersensitivity to antiepileptic drugs. Immunol Allergy Clin N Am. 2014;34:633–43.CrossRef Ye YM, Thong BY, Park HS. Hypersensitivity to antiepileptic drugs. Immunol Allergy Clin N Am. 2014;34:633–43.CrossRef
27.
go back to reference Schiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpes viruses and antiviral and anti drug immune responses. Allergol Int. 2006;55:1–8.CrossRef Schiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpes viruses and antiviral and anti drug immune responses. Allergol Int. 2006;55:1–8.CrossRef
28.
go back to reference Posadas SJ, Pichler WJ. Delayed drug hypersensitivity reactions—new concepts. Clin Exp Allergy. 2007;37(7):989–99.CrossRefPubMed Posadas SJ, Pichler WJ. Delayed drug hypersensitivity reactions—new concepts. Clin Exp Allergy. 2007;37(7):989–99.CrossRefPubMed
29.
go back to reference Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy. 2002;57(1):45–51.PubMed Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy. 2002;57(1):45–51.PubMed
30.
go back to reference Barbaud A. Skin testing and patch testing in non-IgE mediated drug allergy. Curr Allergy Asthma Rep. 2014;14:442.CrossRefPubMed Barbaud A. Skin testing and patch testing in non-IgE mediated drug allergy. Curr Allergy Asthma Rep. 2014;14:442.CrossRefPubMed
31.
go back to reference Barbaud A, Collet E, Milpied B, Assier H, Staumont D, Avenel-Audran M, Grange A, Amarger S, Girardin P, Guinnepain MT, Truchetet F, Lasek A, Waton J, Toxidermies group of the French Society of Dermatology. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol. 2013;168(3):555–62.CrossRefPubMed Barbaud A, Collet E, Milpied B, Assier H, Staumont D, Avenel-Audran M, Grange A, Amarger S, Girardin P, Guinnepain MT, Truchetet F, Lasek A, Waton J, Toxidermies group of the French Society of Dermatology. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol. 2013;168(3):555–62.CrossRefPubMed
32.
go back to reference Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. New Engl J Med. 1994;331:1272–85.CrossRefPubMed Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. New Engl J Med. 1994;331:1272–85.CrossRefPubMed
33.
go back to reference Chave TA, Mortimer NJ, Sladden MJ, Hall AP, Hutchinson PE. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol. 2005;153(2):241–53.CrossRefPubMed Chave TA, Mortimer NJ, Sladden MJ, Hall AP, Hutchinson PE. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol. 2005;153(2):241–53.CrossRefPubMed
34.
go back to reference Kano Y, Shiohara T. The variable clinical picture of drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug. Immunol Allergy Clin N Am. 2009;29:481–501.CrossRef Kano Y, Shiohara T. The variable clinical picture of drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug. Immunol Allergy Clin N Am. 2009;29:481–501.CrossRef
35.
go back to reference Gentile I, Talamo M, Borgia S. Is the drug-induced hypersensitivity syndrome (DIHS) due to human herpes virus 6 infection or to allergy-mediated viral reactivation? Report of a case and literature review. BMN Infect Dis. 2010;10:49.CrossRef Gentile I, Talamo M, Borgia S. Is the drug-induced hypersensitivity syndrome (DIHS) due to human herpes virus 6 infection or to allergy-mediated viral reactivation? Report of a case and literature review. BMN Infect Dis. 2010;10:49.CrossRef
36.
go back to reference Avancini J, Maragno L, Santi CG, Criado PR. Drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome: clinical features of 27 patients. Clin Exp Dermatol. 2015;40(8):851–9.CrossRefPubMed Avancini J, Maragno L, Santi CG, Criado PR. Drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome: clinical features of 27 patients. Clin Exp Dermatol. 2015;40(8):851–9.CrossRefPubMed
37.
go back to reference Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe HC. Lamotrigine and toxic epidermal necrolysis (TEN) in Germany. Lancet. 1996;348:1041.CrossRef Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe HC. Lamotrigine and toxic epidermal necrolysis (TEN) in Germany. Lancet. 1996;348:1041.CrossRef
38.
go back to reference Alvestad S, Lydersen S, Brodtkorb E. Cross-reactivity pattern of rash from current aromatic antiepileptic drugs. Epilepsy Res. 2008;80:194–200.CrossRefPubMed Alvestad S, Lydersen S, Brodtkorb E. Cross-reactivity pattern of rash from current aromatic antiepileptic drugs. Epilepsy Res. 2008;80:194–200.CrossRefPubMed
39.
go back to reference Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia. 2007;48(7):1223–44.CrossRefPubMed Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia. 2007;48(7):1223–44.CrossRefPubMed
40.
go back to reference Lin YF, Yang CH, Sindy H, Lin JY, Rosaline Hui CY, Tsai YC, Wu TS, Huang CT, Kao KC, Hu HC, Chiu CH, Hung SI, Chung WH. Severe cutaneous adverse reactions related to systemic antibiotics. Clin Infect Dis. 2014;58(10):1377–85.CrossRefPubMed Lin YF, Yang CH, Sindy H, Lin JY, Rosaline Hui CY, Tsai YC, Wu TS, Huang CT, Kao KC, Hu HC, Chiu CH, Hung SI, Chung WH. Severe cutaneous adverse reactions related to systemic antibiotics. Clin Infect Dis. 2014;58(10):1377–85.CrossRefPubMed
41.
go back to reference Pichler WJ, Daubner B, Kawabata T. Drug hypersensitivity: flare-up reactions, cross-reactivity and multiple drug hypersensitivity. J Dermatol. 2011;38(3):216–21.CrossRefPubMed Pichler WJ, Daubner B, Kawabata T. Drug hypersensitivity: flare-up reactions, cross-reactivity and multiple drug hypersensitivity. J Dermatol. 2011;38(3):216–21.CrossRefPubMed
42.
go back to reference Schneck J, Gafot JP, Sekula P, Sassolas B, Roujeay JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens–Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008;58:33–40.CrossRefPubMed Schneck J, Gafot JP, Sekula P, Sassolas B, Roujeay JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens–Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008;58:33–40.CrossRefPubMed
43.
go back to reference Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: part II. Management and therapeutics. J Am Acad Dermatol. 2013;68(5):1–9.CrossRef Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: part II. Management and therapeutics. J Am Acad Dermatol. 2013;68(5):1–9.CrossRef
44.
go back to reference Aihara M, Kano Y, Fujita Hm Kambara T, Matsukura S, Katayama I, Azukizawa H, Miyachi Y, Endo Y, Asada H, Miyagawa F, Morita E, Kaneko S, Abe R, Ochiai T, Sueki H, Watanabe H, Nagao K, Aoyama Y, Sayama K, Hashimoto K, Shiohara T, SJS/TEN Study Group. Efficacy of additional i.v. immunoglobulin to steroid therapy in Stevens–Johnson syndrome and toxic epidermal necrolysis. J Dermatol. 2015;42:768–77.CrossRefPubMed Aihara M, Kano Y, Fujita Hm Kambara T, Matsukura S, Katayama I, Azukizawa H, Miyachi Y, Endo Y, Asada H, Miyagawa F, Morita E, Kaneko S, Abe R, Ochiai T, Sueki H, Watanabe H, Nagao K, Aoyama Y, Sayama K, Hashimoto K, Shiohara T, SJS/TEN Study Group. Efficacy of additional i.v. immunoglobulin to steroid therapy in Stevens–Johnson syndrome and toxic epidermal necrolysis. J Dermatol. 2015;42:768–77.CrossRefPubMed
45.
go back to reference Faye O, Roujeay JC. Treatment of epidermal necrolysis with high dose intravenous immunoglobulin (IVIg): clinical experience to date. Drugs. 2005;65:2085–90.CrossRefPubMed Faye O, Roujeay JC. Treatment of epidermal necrolysis with high dose intravenous immunoglobulin (IVIg): clinical experience to date. Drugs. 2005;65:2085–90.CrossRefPubMed
Metadata
Title
Tolerated drugs in subjects with severe cutaneous adverse reactions (SCARs) induced by anticonvulsants and review of the literature
Authors
Fabrizio De Luca
Laura Michelina Losappio
Corrado Mirone
Jan Walter Schroeder
Antonella Citterio
Maria Gloria Aversano
Joseph Scibilia
Elide Anna Pastorello
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Clinical and Molecular Allergy / Issue 1/2017
Electronic ISSN: 1476-7961
DOI
https://doi.org/10.1186/s12948-017-0072-5

Other articles of this Issue 1/2017

Clinical and Molecular Allergy 1/2017 Go to the issue